Loading...
XKRX000230
Market cap54mUSD
Jan 10, Last price  
7,100.00KRW
1D
-2.07%
1Q
-11.58%
Jan 2017
-69.66%
Name

Ildong Holdings Co Ltd

Chart & Performance

D1W1MN
XKRX:000230 chart
P/E
—
P/S
0.13
EPS
—
Div Yield, %
1.72%
Shrs. gr., 5y
0.97%
Rev. gr., 5y
68.47%
Revenues
638.45b
-5.49%
344,579,017,000361,582,105,000376,934,397,000395,940,147,000347,159,849,000348,468,342,530362,781,056,260395,231,104,220417,517,499,000476,385,097,00040,771,268,80041,070,663,19047,050,030,690292,221,432,210596,468,913,500592,374,545,920675,539,717,330638,447,517,670
Net income
-59.59b
L-69.36%
23,119,075,00022,625,593,00018,138,291,00032,846,979,00018,587,293,00027,299,215,00016,887,957,0906,484,818,69011,855,626,23020,979,404,630265,988,145,290651,618,700-3,719,365,090-39,954,887,980-31,271,398,450-134,695,952,280-194,503,503,700-59,586,796,590
CFO
-57.77b
L-22.55%
36,595,211,00016,232,112,000-3,581,963,00049,931,842,00026,011,651,00051,077,885,45018,478,113,52015,648,015,49039,357,140,94056,110,513,91046,643,056,140-2,191,496,7806,233,383,83014,342,013,5908,241,940,680-30,544,994,020-74,588,719,470-57,770,878,108
Dividend
Dec 27, 2023100 KRW/sh
Earnings
Feb 06, 2025

Profile

Ildong Holdings Co., Ltd. develops, manufactures, and supplies pharmaceutical products in South Korea and internationally. It develops new drugs against resistant bacteria, malignant tumors, Alzheimer's disease, obesity, and ageing; and raw vitamins, probiotics, and antimicrobials, as well as offers Biovita, a lactobacillus product; and Aronamin, a multivitamin product. It also engages in the research and manufacture of health foods and ingredients, as well as offers hyaluronic acid for use in drugs, medical devices, and cosmetics; and various medical devices for beauty, cosmetic-surgery, and antiaging applications. In addition, the company distributes medical devices, quasi drugs, health supplements, food products, beverages, cosmetics, sanitary ware, and other healthcare products through online. Further, it offers beauty and cosmetic surgery services; and pharmaceutical SI consulting, system development and deployment, RFID and barcode systems, and other solutions, as well as engages in advertising business. The company was formerly known as Ildong Pharmaceutical Co., Ltd. and changed its name to Ildong Holdings Co., Ltd. in August 2016. Ildong Holdings Co., Ltd. was founded in 1941 and is based in Seoul, South Korea.
URL
http://www.ildongholdings.co.kr/
IPO date
Jun 28, 1975
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
638,447,518
-5.49%
675,539,717
14.04%
Cost of revenue
612,782,290
661,860,587
Unusual Expense (Income)
NOPBT
25,665,227
13,679,130
NOPBT Margin
4.02%
2.02%
Operating Taxes
(13,289,660)
21,553,064
Tax Rate
157.56%
NOPAT
38,954,887
(7,873,934)
Net income
(59,586,797)
-69.36%
(194,503,504)
44.40%
Dividends
(1,377,709)
(1,129,209)
Dividend yield
1.16%
0.50%
Proceeds from repurchase of equity
(2,560,424)
BB yield
2.16%
Debt
Debt current
282,907,089
255,336,260
Long-term debt
56,814,684
79,787,855
Deferred revenue
2,298,615
2,668,968
Other long-term liabilities
102,275,305
90,882,307
Net debt
195,148,678
202,849,415
Cash flow
Cash from operating activities
(57,770,878)
(74,588,719)
CAPEX
(13,487,392)
(21,146,098)
Cash from investing activities
(16,341,622)
(32,504,985)
Cash from financing activities
46,340,199
31,649,245
FCF
(63,330,464)
(11,181,437)
Balance
Cash
102,479,679
136,413,930
Long term investments
42,093,416
(4,139,231)
Excess cash
112,650,720
98,497,714
Stockholders' equity
20,648,838
97,274,420
Invested Capital
579,187,348
479,048,513
ROIC
7.36%
ROCE
4.09%
2.33%
EV
Common stock shares outstanding
11,292
11,292
Price
10,520.00
-47.79%
20,150.00
36.15%
Market cap
118,792,787
-47.79%
227,535,614
36.15%
EV
444,881,176
621,053,384
EBITDA
63,609,254
53,109,854
EV/EBITDA
6.99
11.69
Interest
30,095,656
17,225,381
Interest/NOPBT
117.26%
125.92%